SETH LERNER to Antineoplastic Agents
This is a "connection" page, showing publications SETH LERNER has written about Antineoplastic Agents.
Connection Strength
1.983
-
Novel Thermo-Sensitive Hydrogel Therapy for Low-Grade Upper Tract Urothelial Carcinoma. J Urol. 2021 08; 206(2):191-193.
Score: 0.387
-
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
Score: 0.255
-
Risk-adapted use of intravesical chemotherapy. BJU Int. 2008 Nov; 102(9 Pt B):1247-53.
Score: 0.164
-
Chemoprevention of bladder cancer. World J Urol. 2006 Nov; 24(5):445-72.
Score: 0.143
-
Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urol Oncol. 2003 May-Jun; 21(3):197-205.
Score: 0.112
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
Score: 0.102
-
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res. 2015 Oct 15; 21(20):4514-24.
Score: 0.066
-
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol. 2016 Jan; 34(1):4.e11-7.
Score: 0.066
-
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013 Jun; 11(2):175-81.
Score: 0.054
-
A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma. Urol Oncol. 2013 Feb; 31(2):234-40.
Score: 0.049
-
Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012 May-Jun; 30(3):285-9.
Score: 0.048
-
The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial carcinoma. Curr Treat Options Oncol. 2009 Aug; 10(3-4):267-74.
Score: 0.043
-
Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. Expert Opin Pharmacother. 2008 Aug; 9(11):1885-93.
Score: 0.040
-
Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol. 2008 Jul; 180(1):116-20.
Score: 0.040
-
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
Score: 0.039
-
Neoadjuvant chemotherapy for bladder cancer. Oncology (Williston Park). 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694.
Score: 0.038
-
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006 Jun 15; 106(12):2610-6.
Score: 0.035
-
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 08 01; 7(8):e2425288.
Score: 0.031
-
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU Int. 2024 10; 134(4):596-601.
Score: 0.030
-
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024 Sep; 86(3):258-264.
Score: 0.030
-
Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001 May; 12(5):621-5.
Score: 0.024
-
Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998 Oct 01; 129(7):559-66.
Score: 0.020
-
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia. 1997 Oct; 11(10):1631-5.
Score: 0.019
-
Role of splenectomy in chronic lymphocytic leukemia. J Am Coll Surg. 1997 Sep; 185(3):237-43.
Score: 0.019
-
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73.
Score: 0.018
-
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017 09; 198(3):552-559.
Score: 0.018
-
Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S83-91.
Score: 0.018
-
Bladder cancer. Lancet. 2016 12 03; 388(10061):2796-2810.
Score: 0.017
-
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Sep; 9(9):1444-9.
Score: 0.016
-
Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. Anticancer Drugs. 2014 Sep; 25(8):878-86.
Score: 0.015
-
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther. 2010 May; 9(5):1128-35.
Score: 0.011
-
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002 Sep; 43(9):1755-62.
Score: 0.007
-
Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 2001 Sep; 116(3):437-43.
Score: 0.006